April 16, 2019 — ROCKVILLE, Md.– (BUSINESS WIRE)–NeoImmuneTech, Inc. (NIT), a T cell-focused therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Hyleukin-7TM, a T cell am...

On January 7, 2021, the U.S. FDA Approved Forward IND application for clinical development of FWD1509, which is an innovative drug targeting for non-small cell lung canser(NSCLC) with EGFR exon20 insertion mutation. This clinical development will pro...